These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31764586)

  • 1. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient.
    Kotsis V; Jordan J; Stabouli S; Antza C; Micic D; Jelaković B; Schlaich MP; Nilsson PM; Kreutz R; Mancia G; Tsioufis K; Grassi G
    J Hypertens; 2020 Mar; 38(3):377-386. PubMed ID: 31764586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease.
    Zhang F; Ji L; Hong T; Guo L; Li Y; Zhu Z; Liu X; Liu F; Tang L; Zhang Y; Li J; Lü Q; Tong N
    J Evid Based Med; 2022 Jun; 15(2):168-179. PubMed ID: 35715995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 6. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors.
    Engeli S; Jordan J
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):468-72. PubMed ID: 24914567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
    Busch RS; Kane MP
    Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
    Scheen AJ; Van Gaal LF
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
    Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
    Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 14. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity.
    Nolen-Doerr E; Stockman MC; Rizo I
    Curr Obes Rep; 2019 Sep; 8(3):284-291. PubMed ID: 31124035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk.
    Peters AL
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S20-7. PubMed ID: 19952300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.